Aliri Bioanalysis launches 37 ready-to-use biomarker panels, increasing access to disease insights
Every biomarker in Aliri’s study-ready panels is carefully selected and rigorously verified for its intended biological context
2 Feb 2026Product news
Aliri Bioanalysis launches 37 ready-to-use biomarker panels
Aliri Bioanalysis has translated its years of biomarker research services into two new collections of ready-to-use biomarker panels. The launch features an Oncology Collection and an Immunology & Inflammation Collection, comprising 37 panels and over 48,000 biomarkers.
Compatible with tissue sections, tissue homogenates, cell suspensions, and biological fluids, these expertly curated panels are designed to help researchers address fundamental questions related to disease onset, progression, and therapeutic response.
This new service offering increases translational access to decision-making data about the mechanism of target expression, effectively preventing ambiguous failure in clinical phases. Aliri’s ready-to-use biomarker panels are robust, fast, and cost-effective, eliminating the challenges associated with developing and validating custom panels, which could take months.
Every biomarker in Aliri’s study-ready panels is carefully selected and rigorously verified for its intended biological context.
Sponsors have the flexibility to:
- Select one or multiple ready-to-use panels
- Choose from over 200 standalone biomarkers
- Customize existing panels to add markers of interest
- Design fully bespoke panels tailored to precise scientific objectives
“Drug development starts with understanding the mechanism of the target, how it is expressed, and how it functions and interacts with its microenvironment. This goes far beyond isolated biomarkers and has become critical for robust decision-making in late-stage development.
Aliri’s ready-to-use spatial panels provide immediate access to this biological context, enabling researchers to move faster with confidence by transforming tissue data into predictive insights that support strong development decisions and program success,” says Dr. Corinne Ramos, Aliri's Research & Development Director.
In the coming months, Aliri will release additional ready-to-use biomarker panels, further expanding its ability to deliver robust, translatable, and biologically meaningful data to support disease research and therapeutic development.